Mangoceuticals, Inc.
MGRXHealthcareNASDAQHealth Information Services · Last scanned Oct 24, 2026
Scan Results
Daily timeframeMangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. At a $5.2M market cap, Mangoceuticals, Inc. ranks as a micro-cap company within healthcare. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
Market Cap
$5.2M
Beta
1.98
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.02
EPS (Fwd)
—
ROE
-95.1%
ROA
-47.0%
Cash
$228,688
Total Debt
$279,207
Free CF
$1.3M
52W Change
-90.0%
Annual Financials
Cash vs Debt
Where MGRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MGRX finished 31.71% below its 150-day moving average ($0.41) and 34.88% below its 200-day moving average ($0.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGRX overbought or oversold?
At the October 20, 2026 close, MGRX's RSI(14) was 25.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MGRX has $229K in cash with $279K in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $1.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -95.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $9K to $456K.
With a beta above 1.5, MGRX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mangoceuticals, Inc. and its sector.